# Christopher Ngai

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/christopher-ngai/

## Facts

| Field | Value |
| --- | --- |
| Citations | 740 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 5 |
| i10-index | 5 |
| Last Known Institution | Immunitas Therapeutics (United States) |
| OpenAlex ID | https://openalex.org/A5064011008 |
| ORCID iD | 0000-0003-4136-1550 |
| Works | 24 |

## Researcher papers

- [Synergistic Effects of Traumatic Head Injury and Apolipoprotein-epsilon4 in Patients With Alzheimer's Disease](https://scholariq.org/papers/synergistic-effects-of-traumatic-head-injury-and-apolipoprotein-epsilon4-in/)
- [A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy](https://scholariq.org/papers/a-systematic-literature-review-of-the-epidemiology-health-related-quality-of-2/)
- [A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy](https://scholariq.org/papers/a-systematic-literature-review-of-the-epidemiology-health-related-quality-of/)
- [The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States](https://scholariq.org/papers/the-economic-burden-of-common-adverse-events-associated-with-metastatic/)
- [Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States](https://scholariq.org/papers/cost-effectiveness-analysis-of-nefecon-versus-best-supportive-care-for-people/)
- [Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany](https://scholariq.org/papers/cost-effectiveness-analysis-of-regorafenib-for-gastrointestinal-stromal-tumour/)
- [Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.](https://scholariq.org/papers/effects-of-regorafenib-reg-therapy-on-health-related-quality-of-life-hrqol-in/)
- [P-213 The cost of survival gain in metastatic colorectal cancer (mCRC) in Spain](https://scholariq.org/papers/p-213-the-cost-of-survival-gain-in-metastatic-colorectal-cancer-mcrc-in-spain/)
- [P-212 The cost of survival gain in metastatic colorectal cancer (mCRC) in France](https://scholariq.org/papers/p-212-the-cost-of-survival-gain-in-metastatic-colorectal-cancer-mcrc-in-france/)
- [Results from a Real-World Case Series of Patients with IgAN Who Received at Least 9 Months of Tarpeyo](https://scholariq.org/papers/results-from-a-real-world-case-series-of-patients-with-igan-who-received-at/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Immunitas Therapeutics (United States)](https://scholariq.org/institutions/immunitas-therapeutics-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.